DSGN•benzinga•
Design Therapeutics Announced That The First Friedreich Ataxia Patient Has Been Dosed Via Intravenous Infusion In Its RESTORE-FA Open-label Phase 1/2 Multiple-ascending Dose Trial Of Dt-216P2, Initial Data from the Ongoing, Blinded Phase 1 Single-Ascendin
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 4, 2025 by benzinga